Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 315

1.

Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.

Wiita AP, Roubinian N, Khan Y, Chin-Hong PV, Singer JP, Golden JA, Miller S.

Transpl Infect Dis. 2012 Jun;14(3):248-58. doi: 10.1111/j.1399-3062.2012.00723.x. Epub 2012 Mar 5.

2.

Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.

Lautenschlager I, Loginov R, Mäkisalo H, Höckerstedt K.

J Clin Virol. 2015 Oct;71:73-5. doi: 10.1016/j.jcv.2015.08.009. Epub 2015 Aug 20.

PMID:
26318605
3.

Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.

Mitsani D, Nguyen MH, Kwak EJ, Silveira FP, Vadnerkar A, Pilewski J, Crespo M, Toyoda Y, Bermudez C, Clancy CJ.

J Heart Lung Transplant. 2010 Sep;29(9):1014-20. doi: 10.1016/j.healun.2010.04.022. Epub 2010 Jul 3.

PMID:
20598582
4.

Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.

Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M; VIPP Study Group.

Transplantation. 2012 Jan 15;93(1):61-8. doi: 10.1097/TP.0b013e318238dab3.

PMID:
22094954
5.

Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?

Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A.

Transplant Proc. 2005 Sep;37(7):3182-6.

PMID:
16213344
6.

Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.

Gerbase MW, Dubois D, Rothmeier C, Spiliopoulos A, Wunderli W, Nicod LP.

Chest. 1999 Nov;116(5):1265-72.

PMID:
10559085
7.

Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients.

Johansson I, Mårtensson G, Nyström U, Nasic S, Andersson R.

BMC Infect Dis. 2013 Dec 10;13:582. doi: 10.1186/1471-2334-13-582.

8.

A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients.

Humar A, Kumar D, Preiksaitis J, Boivin G, Siegal D, Fenton J, Jackson K, Nia S, Lien D.

Am J Transplant. 2005 Jun;5(6):1462-8.

9.

A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients.

Monforte V, Lopez C, Santos F, Zurbano F, de la Torre M, Sole A, Gavalda J, Ussetti P, Lama R, Cifrian J, Borro JM, Pastor A, Len O, Bravo C, Roman A.

Am J Transplant. 2009 May;9(5):1134-41. doi: 10.1111/j.1600-6143.2009.02574.x. Epub 2009 Mar 16.

10.

Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.

Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O.

Transplantation. 2011 Jan 27;91(2):251-5. doi: 10.1097/TP.0b013e318200b9f0.

PMID:
21099744
11.

Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.

Shiley KT, Gasink LB, Barton TD, Pfeiffenberger P, Olthoff KM, Blumberg EA.

Liver Transpl. 2009 Aug;15(8):963-7. doi: 10.1002/lt.21769.

12.

Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.

Lopez Garcia-Gallo C, García Fadul C, Laporta R, Portero F, Millan I, Ussetti P.

Ann Transplant. 2015 Nov 5;20:661-6.

13.

Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients.

Helanterä I, Lautenschlager I, Koskinen P.

Nephrol Dial Transplant. 2009 Jan;24(1):316-20. doi: 10.1093/ndt/gfn558. Epub 2008 Oct 8.

PMID:
18842670
14.

Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.

Cervera C, Pineda M, Linares L, Marcos MA, Esteva C, Antón A, Cofán F, Ricart MJ, Navasa M, Pérez-Villa F, Pumarola T, Moreno A.

Transplant Proc. 2007 Sep;39(7):2228-30.

PMID:
17889146
15.

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients.

Doesch AO, Repp J, Hofmann N, Erbel C, Frankenstein L, Gleissner CA, Schmidt C, Ruhparwar A, Zugck C, Schnitzler P, Ehlermann P, Dengler TJ, Katus HA.

Drug Des Devel Ther. 2012;6:289-95. doi: 10.2147/DDDT.S36578. Epub 2012 Oct 12.

16.

High incidence of cytomegalovirus disease in D+/R- heart transplant recipients shortly after completion of 3 months of valganciclovir prophylaxis.

Gupta S, Mitchell JD, Markham DW, Mammen PP, Patel PC, Kaiser P, Ring WS, DiMaio JM, Drazner MH.

J Heart Lung Transplant. 2008 May;27(5):536-9. doi: 10.1016/j.healun.2008.02.002.

PMID:
18442720
17.

Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.

Perrottet N, Manuel O, Lamoth F, Venetz JP, Sahli R, Decosterd LA, Buclin T, Pascual M, Meylan P.

BMC Infect Dis. 2010 Jan 6;10:2. doi: 10.1186/1471-2334-10-2.

18.

Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.

Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK.

Pharmacotherapy. 2004 Oct;24(10):1323-30.

PMID:
15628830
19.

Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.

McKeen JT, Tsapepas DS, Li H, Anamisis A, Martin ST.

Prog Transplant. 2015 Mar;25(1):39-44. doi: 10.7182/pit2015558.

PMID:
25758799
20.

Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy.

Reddy V, Hao Y, Lipton J, Meharchand J, Minden M, Mazzulli T, Chan C, Messner HA.

J Clin Virol. 1999 Aug;13(3):149-59.

PMID:
10443791

Supplemental Content

Support Center